TICKERNERD
Menu
BMYBMYHealthcare · Drug Manufacturers - General

BMY Stock Forecast: Bristol Myers Squibb Co. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$60
+1.33% on the day

The 28 Wall Street analysts covering Bristol Myers Squibb Co. hold a median 12-month price target of $68 — +14.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 6 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$124.9B
Ticker Nerd rank
99 / 100
Median analyst target
$68
Analysts covering
28
Revenue$13.0B+5.7% y/y
Operating income$4.0B
Net income$3.3B
Free cash flow$3.1B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.2%
1M
−9.9%
YTD
+15.3%
1Y
+37.8%
From 52W high
−11.6%
From 52W low
+46.0%
$41
$67
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BMY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bristol Myers Squibb Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
99 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
100
Volatility
100
Revisions
98
Issuance
93
Quality
92
Momentum
85
Growth
68
Accruals
65
Size
2

Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (65): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BMY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BMY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$50$60$70$80Jan 26Apr 26Jul 26Oct 26BMYHigh $82Median $68Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says28 analysts
9 Buy18 Hold1 Sell
Low $40Median $68High $82

The green dot is the last close — the median target sits +14.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
16 Sept 2026Piper SandlerReiteratesOverweight$75 → $82
10 Sept 2026HSBCMaintainsHold$60 → $65
5 Aug 2026Argus ResearchUpgradeBuy—
5 Aug 2026Argus ResearchUpgradeBuy$75
3 Aug 2026CitigroupMaintainsNeutral—
3 Aug 2026CitigroupMaintainsNeutral$66 → $70
31 July 2026Cantor FitzgeraldMaintainsNeutral$54 → $59
31 July 2026Cantor FitzgeraldMaintainsNeutral—
31 July 2026GuggenheimMaintainsBuy—
31 July 2026GuggenheimMaintainsBuy$72 → $75
31 July 2026JP MorganMaintainsOverweight—
31 July 2026JP MorganMaintainsOverweight$67 → $73
31 July 2026RBC CapitalMaintainsSector Perform$60 → $64
31 July 2026RBC CapitalMaintainsSector Perform—
31 July 2026Truist SecuritiesReiteratesBuy$65 → $70
31 July 2026Truist SecuritiesReiteratesBuy—
31 July 2026Wells FargoMaintainsEqual-Weight—
31 July 2026Wells FargoMaintainsEqual-Weight$60 → $65
10 July 2026B of A SecuritiesMaintainsBuy$67 → $66
10 July 2026B of A SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BMY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BMY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Bristol Myers Squibb Co. returned +37.8% against +17.3% for the S&P 500, dividends included.

BMY vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150160Jan 26Apr 26Jul 26Oct 26BMYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BMY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+10.1%
Analysts raising
25
Analysts cutting
0
Fundamentals

Bristol Myers Squibb Co. (BMY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
13.5×

Cheaper than 49% of US stocks

Price / sales
2.5×

Cheaper than 46% of US stocks

Price / book
5.6×

Cheaper than 18% of US stocks

EV / EBITDA
8.4×

Cheaper than 43% of US stocks

Growth & margins
Revenue growth (YoY)
5.7%

Higher than 41% of US stocks

Earnings growth (YoY)
153.2%

Higher than 88% of US stocks

Gross margin
71.3%

Higher than 84% of US stocks

Operating margin
34.4%

Higher than 89% of US stocks

Net margin
18.9%

Higher than 81% of US stocks

Returns & dividend
Return on equity
46.6%

Higher than 92% of US stocks

Return on assets
10.7%

Higher than 93% of US stocks

Dividend yield
4.1%

Higher than 91% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Bristol Myers Squibb Co. (BMY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Bristol Myers Squibb Co. has a market value of $124.9B and an enterprise value of $158.9B.

  • Revenue in the twelve months to 30 June 2026: $49.2B. The latest quarter grew 5.7% year on year.

  • Net income over the same four quarters: $9.3B, a 18.9% net margin.

  • Diluted earnings per share, trailing twelve months: $4.54.

  • Free cash flow in the twelve months to 30 June 2026: $11.4B, after $1.3B of capital spending.

  • Bristol Myers Squibb Co. spent $5.1B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 2.0B.

  • Trailing P/E: 13.5×; forward P/E: 9.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 4.12%, paying out 55% of earnings.

  • Bristol Myers Squibb Co. employs 32,500 people — $1.5M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

BMY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
BMYBristol Myers Squibb Co.$124.9B
99
PFEPfizer Inc.$156.4B
82
GILDGilead Sciences, Inc.$179.1B
94
AMGNAmgen, Inc.$217.0B
93
MRKMerck & Co., Inc.$352.3B
83
BIIBBiogen, Inc.$32.7B
76
ABBVAbbVie, Inc.$471.2B
96

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bristol Myers Squibb Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BMY news & analysis

BMY or ARGX: Which Is the Better Value Stock Right Now?

Zacks Investment Research · 5 Oct 2026neutral

A Zacks Investment Research article compares Bristol Myers Squibb (BMY) with argenx SE (ARGX), both in the Medical - Biomedical and Genetics sector, to determine which presents the better value opportunity for investors right now.

Why it matters — BMY watchers would care because the piece evaluates the company's value proposition relative to a sector peer, offering context on investor perceptions.

Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now?

Zacks Investment Research · 5 Oct 2026neutral

Zacks Investment Research published a piece asking whether investors are currently undervaluing Bristol Myers Squibb (BMY). The article discusses the Zacks Rank system, which focuses on earnings estimates and estimate revisions, while also considering value, growth, and momentum trends.

Why it matters — BMY watchers would be interested in the question of whether the stock is undervalued and how it fares under Zacks' earnings-estimate and valuation framework.

3 Stocks With Broker Rating Upgrades Amid Resilient Equity Markets

Zacks Investment Research · 5 Oct 2026positive

Zacks Investment Research reported that Bristol Myers Squibb received a broker rating upgrade, along with Dollar General and Equinor, against a backdrop of resilient U.S. equity markets and projected earnings growth.

Why it matters — A broker rating upgrade for Bristol Myers Squibb signals improved analyst sentiment, which BMY watchers would view as a favorable development.

Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy?

The Motley Fool · 3 Oct 2026neutral

The article discusses Bristol Myers Squibb's valuation, noting it trades at 9.4 times forward earnings. It highlights that the company has faced patent cliffs in recent years, with more expected, but appears relatively well equipped to manage these challenges moving forward.

Why it matters — A BMY watcher would care because the item assesses the company's valuation and its capacity to navigate upcoming patent expirations, key factors influencing its long-term earnings outlook.

Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?

Zacks Investment Research · 2 Oct 2026neutral

Bristol Myers Squibb's Camzyos has gained a broader FDA label and posted strong sales growth. However, emerging competition and pipeline setbacks are shaping the company's cardiovascular outlook.

Why it matters — A BMY watcher would care because Camzyos' label expansion and sales momentum are key to the company's cardiovascular portfolio, while competitive and pipeline challenges could affect that growth.

FAQ

Frequently asked questions about BMY stock

What is the BMY stock price forecast for 2026-2027?

The 28 Wall Street analysts covering Bristol Myers Squibb Co. have a median 12-month price target of $68, with estimates ranging from $40 to $82. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BMY stock a buy right now?

Of the 28 analysts covering Bristol Myers Squibb Co., 9 rate it a Buy, 18 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bristol Myers Squibb Co. 99 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BMY?

As at 6 Oct 2026, Bristol Myers Squibb Co. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).

Will BMY stock go up?

No one can know that. What the data says: the median 12-month target from 28 analysts implies +14.1% from the last close, and Ticker Nerd's factor model ranks Bristol Myers Squibb Co. 99 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BMY stock forecast for 2030?

No analyst covering Bristol Myers Squibb Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $82 over the next 12 months.

How has BMY stock performed over the past year?

Bristol Myers Squibb Co. returned +37.8% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bristol Myers Squibb Co. do?

Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for serious diseases. Bristol-Myers Squibb Company focuses on major therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, serving patients with complex and often chronic conditions.

What is the latest news on BMY?

The most recent item we track (Zacks Investment Research, 5 Oct 2026): "BMY or ARGX: Which Is the Better Value Stock Right Now?". A Zacks Investment Research article compares Bristol Myers Squibb (BMY) with argenx SE (ARGX), both in the Medical - Biomedical and Genetics sector, to determine which presents the better value opportunity for investors right now.

Company

About Bristol Myers Squibb Co.

Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for serious diseases. Bristol-Myers Squibb Company focuses on major therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, serving patients with complex and often chronic conditions. Its portfolio includes small-molecule drugs, biologics, and cell therapies, reflecting a broad approach to advanced treatment design and delivery. The company supports healthcare systems through research-driven products used in hospitals, specialty clinics, and outpatient care settings around the world. Bristol-Myers Squibb Company plays an important role in the pharmaceutical market by providing therapies aimed at difficult-to-treat illnesses and by maintaining a diversified pipeline and product mix across multiple disease categories.

CEO Dr. Christopher S. Boerner Ph.D. · 32,500 employees · United States · https://www.bms.com